Citations

Clear

4610 citation(s) found for "Lu, Brian".

Artifacts in Urodynamic Studies: A Narrative Review
Pourghazi, Farzad , Linder, Brian J. , Linder, Brian J , Alizad, Azra , Fatemi, Mostafa

Mayo Clinic

Neurourology and Urodynamics | August 20, 2025 | Volume: 44 | Issue: 8 | Pages: 1583-1592

10.1002/nau.70128 | PMID 40831019 Get It

ABSTRACT Background Urodynamic studies (UDS) are integral to the evaluation and management of lower urinary tract dysfunction. However, artifacts are frequently encountered, affecting both clinical interpretation and research reliability. Objective This expert narrative review examines the prevalence, classification, and clinical relevance of artifacts encountered during UDS, based on findings from the existing literature. Methods A focused literature review was conducted, analyzing studies that reported data on the sources and impact of UDS artifacts, particularly from the patient perspective. Emphasis was placed on identifying both technical and patient‐related contributors to artifact generation. Results Artifacts are common in UDS despite adherence to Good Urodynamic Practices recommended by the International Continence Society. Technical artifacts may stem from equipment‐related issues such as calibration errors, catheter displacement, and device variability. Patient‐related artifacts can arise from physical movement or test‐induced detrusor overactivity. These artifacts may lead to misinterpretation, misdiagnosis, and inappropriate interventions in clinical practice. Furthermore, they may affect the validity of research findings related to diagnostic tools for lower urinary tract symptoms. Conclusion Identifying and addressing UDS artifacts during the procedure or in post‐test interpretation is critical for accurate clinical decision‐making and reliable research outcomes. Efforts to minimize artifacts should be prioritized to improve the quality and utility of UDS.
Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study
Herrera, Alex F. , Ansell, Stephen M. , Zinzani, Pier Luigi , Maddocks, Kami J. , Pinto, Antonio , Collins, Graham P. , Bachanová, Veronika , Bartlett, Nancy L. , Bence‐Bruckler, Isabelle , Mayer, Jiří , Advani, Ranjana H. , Feldman, Tatyana , Hess, Brian , Szomor, Árpád, André, Marc, Dyczkowski, Jerzy, Havenith, Karin , Toukam, Marie , Pantano, Serafino, Cruz, Hans G. , Wang, Luqiang, Negievich, Yanina, Lucero, Melanie , Wuerthner, Jens, Carlo‐Stella, Carmelo , Radford, John , Pinto, Antonio , Bartlett, Nancy L , Hamadani, Mehdi , Savage, Kerry J , Casasnovas, René-Olivier , Iyengar, Sunil , Townsend, William , Cruz, Hans G , Carlo-Stella, Carmelo , Bachanova, Veronika , Zinzani, Pier Luigi , Advani, Ranjana H , Radford, John , Collins, Graham P., Hamadani, Mehdi , Kline, Justin Paul , Savage, Kerry J. , Caimi, Paolo F. , Casasnovas, Olivier , Bastos‐Oreiro, Mariana , Townsend, William

Mayo Clinic

Blood Advances | August 14, 2025 | Volume: 9 | Issue: 23 | Pages: 6205-6217

10.1182/bloodadvances.2024015600 | PMID 40811783 Get It

Abstract Outcomes in classic Hodgkin lymphoma (cHL) have steadily improved; however, additional therapies are needed for patients who relapse or do not respond to novel agents. Here, we report the efficacy and safety of camidanlumab tesirine (Cami), an anti-CD25 antibody-drug conjugate, in patients with relapsed/refractory cHL after brentuximab vedotin/programmed cell death protein 1 inhibitor therapies from the phase 2 ADCT-301-201 study. Eligible patients were adults with cHL who had received ≥3 previous lines of systemic therapy (or ≥2 if ineligible for hematopoietic stem cell transplant). Patients received 45 μg/kg Cami (IV, once every 3 weeks) in cycles 1 to 2, followed by 30 μg/kg IV once every 3 weeks for ≤1 year. The primary end point was overall response rate (ORR) per 2014 Lugano classification. Secondary end points included complete response rate (CRR), progression-free survival (PFS), and overall survival (OS). In total, 117 patients were enrolled with a median age of 37.0 years (range, 19-87). The ORR was 70.1% (95% confidence interval [CI], 60.9-78.2), with a CRR of 33.3% (95% CI, 24.9-42.6). The median PFS was 9.13 months (95% CI, 5.3-15.0); median OS was not reached. Thirty-three (28.2%) patients discontinued treatment because of treatment-emergent adverse events; the most common reasons were skin and subcutaneous tissue disorders (n = 10 [8.5%] patients), infections and infestations (n = 5 [4.3%]), and nervous systems disorders (n = 5 [4.3%]). Guillain-Barré–type or polyradiculopathy-type events occurred in 8 (6.8%) patients. Cami was efficacious in this heavily pretreated population; however, the efficacy was overshadowed by substantial issues with the safety profile. This trial was registered at www.clinicaltrials.gov as #NCT04052997.
Caregiver experiences after the death of a person with dementia with Lewy bodies: A mixed-methods analysis
Armstrong, Melissa J. , Dai, Yunfeng , LaBarre, Brian , Wang, Tingchang , Sovich, Kaitlin , Jury, Hannah F , Henriquez, Adolfo M , Maixner, Susan M. , Paulson, Henry L. , Fields, Julie A. , Lunde, Angela , Manning, Carol A. , Taylor, Angela , Dai, Yunfeng , LaBarre, Brian , Wang, Tingchang , Jury, Hannah F , Henriquez, Adolfo M , Maixner, Susan M , Lunde, Angela M , Boeve, Brad , Baker, Zachary G , Paulson, Henry L , Armstrong, Melissa J , Wollney, Easton N. , Li, Zhigang , Galvin, James E. , Boeve, Bradley F.

Mayo Clinic

Journal of Alzheimer’s Disease | August 14, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/13872877251365218 | PMID 40808538 Get It

Background Dementia with Lewy bodies (DLB) is a common degenerative dementia, but no studies investigate bereaved caregiver experiences. Objective To investigate the experiences of caregivers three months after the death of persons with DLB using a mixed-methods approach. Methods Dyads of individuals with moderate-advanced DLB and their primary informal caregivers were followed prospectively every 6 months until the person with DLB died. Caregivers completed a study visit with questionnaires and a semi-structured interview ∼3 months later. Spearman correlation coefficients and Wilcoxon rank-sum tests evaluated the relationships of post-death measures with pre-death patient and caregiver variables. Thematic analysis was used to analyze the interviews. Results Seventy-three caregivers completed visits (mean 3.5 months post-death). Most of the caregivers were women (82.2%) and spouses (76.7%) or adult children (17.8%). Over 40% had scores indicating risk for clinical depression. Post-death caregiver experiences (depression, quality of life, grief, resilience) correlated with pre-death caregiver experiences. Post-death experiences did not associate with patient characteristics, disease-related symptoms, or healthcare services used in the last 6 months of life. Trajectories for caregiver measures from pre- to post-death visits varied widely. Interview themes included grief and sadness, anger, guilt and regret, relief, appreciation/gratitude, and adjusting to a new normal. Conclusions The finding that pre-death caregiving experiences have the strongest association with post-death experiences emphasizes the critical importance of accessible and evidence-based caregiver support before and after the death of a person with DLB. Research is needed to develop interventions for current and bereaved caregivers of individuals with DLB. Trial registration information NCT04829656 (submitted 2021-03-22).
Sarcoma Patient Narratives With Respect to the Social Determinants of Health: A Thematic Analysis
Peairs, Emily M. , Morrissette, Kali , Shenoy, Devika A , Levine, Nicole L. , Lunn, Kiera , Sachs, Elizabeth , Brigman, Brian E. , Eward, William C. , Visgauss, Julia D. , Visgauss, Julia D , Cook, Chad E.

Mayo Clinic

Psycho-Oncology | August 14, 2025 | Volume: 34 | Issue: 8 | Pages: No page available

10.1002/pon.70257 | PMID 40804031 Get It

ABSTRACT Objectives Sarcomas are rare, mesenchymal tumors that require multimodality treatment provided by multidisciplinary teams. This study seeks to better understand sarcoma patient narratives and quality of life in relation to the social determinants of health (SDoH). Methods Eligible patients who were diagnosed with sarcoma, treated by our institution's orthopedic oncology team, and identified with at least one social risk factor were contacted about participating in a semi‐structured interview. SDoH information collected included (1) Economic Stability, (2) Access to Health Care, (3) Neighborhood & Physical Environment, (4) Social & Community Context, and (5) Education Access and Quality. Interviews were then recorded, de‐identified, transcribed, and coded by reviewers. The validated Framework Method for qualitative research was used to summarize themes. Descriptive statistics were used to summarize the percentage of participants that identified with each SDoH concern. Results 100% of patients ( N = 17) discussed how quality and access to healthcare affected their experience. 88.2% of participants expressed the importance of transportation. 29.4% of participants discussed how they thought their educational background affected their cancer care. Other common themes centered around social support, employment, financial security, and insurance. Conclusion Our research elicited ways in which SDoH affected the care experience of patients with sarcoma. The identified domains offer clinicians valuable information into non‐clinical factors, such as employment concerns or transportation issues, that may affect care for patients with sarcoma. Interdisciplinary care providers (social workers, psychologists, financial navigators) may also help promote open dialogues with patients about their social circumstances and actively facilitate connections to institutional resources or community support systems.
Microbiome and resistome characterization of patients colonized with carbapenem-resistant Enterobacterales by long-read metagenomic next-generation sequencing of rectal swabs
Fissel, John A. , Bergman, Yehudit , Campodónico, Victoria L. , Walsh, Dana M. , Fanelli, Brian , Arogyaswamy, Keshav, Kwon, Jennie H. , Milstone, Aaron M. , Tamma, Pranita D. , Simner, Patricia J. , Tamma, Pranita D , Bergman, Yehudit

Mayo Clinic

JAC-Antimicrobial Resistance | August 12, 2025 | Volume: 7 | Issue: 4 | Pages: No page available

10.1093/jacamr/dlaf152 | PMID 40894237 Get It

Abstract Objectives Evaluation of differences in the intestinal microbiome and resistome among high-risk patients (i.e. intensive care, oncology, transplant recipients) who are and are not colonized with carbapenem-resistant Enterobacterales (CRE). Methods One hundred and twelve rectal swabs were obtained from 85 patients with known CRE colonization status and cohorted. Long-read metagenomic next-generation sequencing (mNGS) was performed on rectal swabs. Microbiome and resistome analysis were performed by assessing α-diversity, β-diversity, relative abundance assessment and linear discriminant analysis effect size (LEfSe), comparing patients colonized (CRE positive) and not colonized (CRE negative) with CRE. Longitudinal analysis of sequential swabs collected over multiple hospital encounters on a subset of patients was performed at the patient level. Results The microbiomes of cohorts were similar when comparing α- and β-diversity measures and relative abundance. LEfSe analysis identified Gram-negative pathobionts enriched among CRE-positive samples and Gram-positive taxa enriched among CRE-negative samples. α-Diversity of the resistome differed at class, gene and allele levels. Relative abundance and LEfSe analysis demonstrated enrichment of genes conferring β-lactam resistance among CRE-positive patients; LEfSe also demonstrated enrichment of antimicrobial resistance genes to multiple antimicrobial classes. At the patient level, fluctuations in the microbiome and resistome among longitudinally collected swabs were associated with antibiotic exposure. Conclusions Differences between the microbiomes of CRE-positive- and CRE-negative-colonized patients at the cohort level were relatively muted, whereas statistically significant differences were observed among their resistomes. In patients followed longitudinally, shifts in microbiome and resistome composition were dramatic in between encounters and antibiotic exposures.
Comparison of High‐Resolution Anorectal Manometry and Magnetic Resonance Defecography in Patients With Obstructive Defecation: Are Both Tests Necessary?
Vora, Haily, Lacy, Brian E. , Lacy, Brian E

Mayo Clinic

Neurogastroenterology & Motility | August 11, 2025 | Volume: 37 | Issue: 11 | Pages: No page available

10.1111/nmo.70131 | PMID 40787901 Get It

ABSTRACTIntroductionInvestigation of an evacuation disorder is often pursued in patients with symptoms of obstructive defecation. High‐resolution anorectal manometry (HR‐ARM) is a simple, safe, and widely available test to diagnose pelvic floor dysfunction. A more costly and less accessible test is magnetic resonance defecography (MRD). This study aims to quantify the added value of MRD in diagnosing pelvic floor disorders.MethodsHR‐ARM and MRD performed in patients with a diagnosis of constipation between January 1, 2020 and May 15, 2022 at Mayo Clinic were identified using Epic Slicer Dicer. Univariate and multivariate analyses were used to compare findings on MRD in patients with and without abnormal HR‐ARM. Categorical variables were compared using the Pearson's chi‐square test, and continuous variables were compared using the two‐sample t‐test.ResultsSeventy‐six consecutive patients (81.8% female, 94.8% White, ages 19–82) who underwent both HR‐ARM and MRD were included. The majority had evidence of dyssynergia on HR‐ARM (n = 49, 64.5%). Patients with dyssynergia on HR‐ARM were significantly more likely to have prolonged balloon expulsion at both > 60 and > 30 s (p < 0.001) and incomplete gel expulsion on MRD (p < 0.001). However, they were not more likely to have a clinically significant rectocele measuring > 2 cm (p = 0.17) or evidence of rectal prolapse (p = 0.07).DiscussionAnatomic findings on MRD were similar between patients with and without evidence of dyssynergia identified by HR‐ARM. In this retrospective review, simultaneously undergoing MRD in addition to HR‐ARM does not appear to provide significant additional diagnostic information to guide therapeutic recommendations. Large prospective studies to evaluate the added value of MRD are needed.
Connectivity as a universal predictor of tau progression in atypical Alzheimer’s disease
Bruin, Hannah de , Groot, Colin , Barthel, Henryk , Bischof, Gérard N. , Boon, Baayla D.C. , Brendel, Matthias , Cash, David M. , Coath, William , Day, Gregory S. , Dyck, Christopher H. van , Fredericks, Carolyn , Fryer, Tim D. , Graff‐Radford, Jonathan , Hobbs, Diana A. , Hoenig, Merle C. , Josephs, Keith A. , Katsumi, Yuta , Joie, Renaud La , Xiong, Chengjie , Malpetti, Maura , McGinnis, Scott M., Mecca, Adam P. , O’Brien, John T. , Putcha, Deepti , Rabinovici, Gil D. , Rahmouni, Nesrine , Rullmann, Michael , Saur, Dorothee , Servaes, Stijn , Sintini, Irene , Stevenson, Jenna , Stomrud, Erik , Strandberg, Olof, Tideman, Pontus , Touroutoglou, Alexandra , Trainer, Anne, Wekselman, Fattin, Weston, Philip S.J. , Whitwell, Jennifer L. , Yong, Keir , de Bruin, Hannah , Brendel, Matthias , Cash, David M , Coath, William , Dickerson, Bradford Clark , van Eimeren, Thilo , van der Flier, Wiesje M , Fredericks, Carolyn A , Gordon, Brian A , Graff-Radford, Jonathan , Grinberg, Lea , Hansson, Oskar , Irwin, David J , Josephs, Keith A , Katsumi, Yuta , La Joie, Renaud , Lee, Edward B , Xiong, Chengjie , Malpetti, Maura , Mohanty, Rosaleena , O'Brien, John Tiernan , Palleis, Carla , Phillips, Jeffrey S , Putcha, Deepti , Rosa-Neto, Pedro , Schott, Jonathan M , Schroeter, Matthias L , Smith, Ruben , Spina, Salvatore , Therriault, Joseph , Whitwell, Jennifer , Yong, Keir X X , Franzmeier, Nicolai , Day, Gregory S , Stomrud, Erik , Rabinovici, Gil D , Blazhenets, Ganna , Boellaard, Ronald , Doering, Elena , Drzezga, Alexander E. , Flier, Wiesje M. van der , Giessen, Elsmarieke van de , Gordon, Brian A. , Grinberg, Lea T. , Hansson, Oskar , Höglinger, Günter U. , Irwin, David J. , Jones, Peter Simon , Lee, Edward B. , Mohanty, Rosaleena , Nasrallah, Ilya M. , O’Dell, Ryan S. , Perneczky, Robert , Rowe, James B. , Sabri, Osama , Schildan, Andreas , Schott, Jonathan M. , Seeley, William W. , Servaes, Stijn , Spina, Salvatore , Visser, Denise , Wolk, David A. , Pijnenburg, Yolande A.L. , Franzmeier, Nicolai , Ossenkoppele, Rik

Mayo Clinic

Brain | August 8, 2025 | Volume: 148 | Issue: 11 | Pages: 3893-3912

10.1093/brain/awaf279 | PMID 40810361 Get It

Abstract The link between regional tau load and clinical manifestation of Alzheimer’s disease (AD) highlights the importance of characterizing spatial tau distribution across disease variants. In typical (memory-predominant) AD, the spatial progression of tau pathology mirrors the functional connections from temporal lobe epicentres. However, given the limited spatial heterogeneity of tau in typical AD, atypical (non-amnestic-predominant) AD variants with distinct tau patterns provide a key opportunity to investigate the universality of connectivity as a scaffold for tau progression. In this large-scale, multicentre study across 14 international sites, we included cross-sectional tau-PET data from 320 individuals with atypical AD (n = 139 posterior cortical atrophy/PCA-AD; n = 103 logopenic variant primary progressive aphasia/lvPPA-AD; n = 35 behavioural variant AD/bvAD; n = 43 corticobasal syndrome/CBS-AD), with a subset of individuals (n = 78) having longitudinal tau-PET data. Additionally, as an independent sample, we included regional post-mortem tau stainings from 93 atypical AD patients from two sites (n = 19 PCA-AD, n = 32 lvPPA-AD, n = 23 bvAD, n = 19 CBS-AD). Gaussian mixture modelling was used to harmonize different tau-PET tracers by transforming tau-PET standardized uptake value ratios to tau positivity probabilities (a uniform scale ranging from 0% to 100%). Using linear regression, we assessed whether brain regions with stronger resting-state functional MRI-based functional connectivity, derived from healthy elderly controls in the Alzheimer’s Disease Neuroimaging Initiative (ADNI), showed greater covariance in cross-sectional and longitudinal tau-PET and post-mortem tau pathology. Furthermore, we examined whether functional connectivity of tau-PET epicentres (i.e. the top 5% of regions with the highest baseline tau load) and tau-PET accumulation epicentres (i.e. the top 5% of regions with the highest tau accumulation rates) was associated with cross-sectional and longitudinal tau patterns. Our findings show that tau-PET epicentres aligned with clinical variants, e.g. a visual network predominant pattern in PCA-AD (‘visual AD’) and left-hemispheric temporal predominance, particularly within the language network, in lvPPA-AD (‘language AD’). Moreover, more strongly functionally connected regions showed correlated concurrent tau-PET levels (confirmed with post-mortem data) and tau-PET accumulation rates. The functional connectivity profile of tau-PET epicentres and accumulation epicentres corresponded to tau-PET progression patterns, with higher tau-PET levels and accumulation rates in functionally close regions, and lower tau-PET levels and accumulation rates in functionally distant regions. Our data are consistent with the hypothesis that tau propagation occurs along functional connections originating from local epicentres, across all AD clinical variants. Since tau proteinopathy is a major driver of neurodegeneration and cognitive decline, this finding may advance personalized medicine and participant-specific end points in clinical trials.
Recent Progress in the Field of Artificial Organs
Ursoleo, Jacopo D’Andria , Woolley, Brian E. , Curran, Brett F., Doran‐Gallastegi, Ander, Treffalls, John A. , D'Andria Ursoleo, Jacopo , Shah, Aakash

Mayo Clinic

Artificial Organs | August 7, 2025 | Volume: 49 | Issue: 10 | Pages: 1483-1485

10.1111/aor.70002 | PMID 40772601 Get It

Short bowel syndrome–associated intestinal failure patient experience: A mixed‐method study leveraging an online patient community
Feldman, Josh , Gower, Megan, Kirby, Michelle, Terreri, Brian , Mundi, Manpreet S. , Feldman, Josh , Mundi, Manpreet S , Chen, Brian , McCue, Maggie

Mayo Clinic

Nutrition in Clinical Practice | August 7, 2025 | Volume: 40 | Issue: 5 | Pages: 1115-1124

10.1002/ncp.70002 | PMID 40772483 Get It

Abstract Background Patients with short bowel syndrome–associated intestinal failure (SBS‐IF) require complex, personalized, and multidisciplinary care; however, there are disparities in access. This study measured the impact of unmet needs and treatment burden among patients and their caregivers. Methods This cross‐sectional, mixed‐method study included US adults self‐reporting SBS‐IF and receiving home parenteral nutrition for ≥6 months and their caregivers. One‐hour interviews informed the development of a 30‐min survey administered to participants from an online health community. Results Among 68 patients, the mean age was 42 years, 79% were female, and 88% were White. Most of the 16 caregivers were female (69%), and younger than 45 years (69%). Of 32 patients (47%) receiving care from an SBS specialist, only 19 (59%) were referred after diagnosis; in 58% of these, referral occurred >6 months after diagnosis. Depression was reported in 44 patients (65%), with 54% not receiving professional mental health care. Financial concerns were common, with 44 patients (65%) unable to work and 40 patients (59%) reporting annual household income of <$50,000. Of 32 patients reporting difficulty paying medical bills, 22 (32%) could not fill prescriptions and 19 (28%) canceled/delayed healthcare provider visits. Social determinant of health challenges were reported by 44 patients (65%). Caregivers' responsibilities impacted their ability to work (50%) and future outlook (63%). Conclusion Patients with SBS‐IF face difficulties accessing specialized healthcare, and are at risk of adverse healthcare outcomes, financial hardships, and poor quality of life. Mental health and work/financial issues were common among both patients and caregivers.
Characterizing primary mediastinal large B-cell lymphoma based on molecular classification: a multi-center retrospective pilot study
Superdock, Michael , Rimsza, Lisa M. , Strawderman, Myla , Ramsower, Colleen , Steiner, Raphaël , Faugh, Tina, Maurer, Matthew J. , Feldman, Andrew L., Rock, Philip , Robetorye, Ryan S. , Flowers, Christopher R. , Friedberg, Jonathan W. , Maurer, Matthew , Rosenthal, Allison C, Wallace, Danielle , Link, Brian K. , Rosenthal, Allison , Burack, Richard , Syrbu, Sergei , Feldman, Andrew L. , Cerhan, James R. , Casulo, Carla

Mayo Clinic

Leukemia & Lymphoma | August 6, 2025 | Volume: 66 | Issue: 12 | Pages: 2324-2327

10.1080/10428194.2025.2539231 | PMID 40768371 Get It